Pharm Exec Names Januvia Brand of the Year - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharm Exec Names Januvia Brand of the Year

ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck's Januvia [sitagliptin], a first in class dipeptide peptidase-4 inhibitor treatment for adult onset [Type II] diabetes, was named 2013 Brand of the Year by Pharmaceutical Executive magazine.

Brand of the Year is an independent, non-promotional designation, selected annually since 1998 by the publication's editorial staff and advisory board. It seeks to recognize FDA-authorized prescription medicines with a track record of clinical innovation as well as consistent, real-world performance and appeal to patients. It must also demonstrate novelty in the developer's approach to brand-building and market awareness activities.

Januvia was developed and has been marketed by Merck since 2006, and, along with its sister drug Janumet, is now the biggest-selling therapeutic franchise in the company's 122-year history. "We are pleased to devote our March cover to this important medicine, not only because of its breakthrough status in regulating blood sugar among Type II patients, with fewer side effects, but also for the higher profile it has given to a debilitating chronic condition that contributed to the deaths of more than 4.6 million people worldwide in 2011," said Pharm Exec Editor-in-Chief William Looney.

An article, authored by Senior Editor Ben Comer, features interviews and backgrounders with several top Merck executives, representatives of the original product launch team, patient groups and independent medical experts, all of whom point to the need for further progress by the pharmaceutical industry in combating persistent challenges in managing this growing illness. Despite the success of clinically effective medicines like Januvia, half of all diabetes patients still fail to complete the drug therapy recommended by their physician.  

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here